Aditya Bardia
Program Director, Breast Medical Oncology & Assistant Chief, Translational Research, Hematology/Oncology Division UCLA Health
Seminars
- Contextualizing ADC clinical class effect toxicities to understand barriers to progression to standard of care and early-stage therapies
- Explaining the physician’s perspective and patient attitudes to ADC treatments given anti-tumor efficacy and associated toxicity profiles
- Breaking down clinical toxicity mitigation strategies: What are the top learnings to pass back to ADC developers?